A Japanese unit of British drugmaker AstraZeneca said Thursday that it has applied for approval from the health ministry to manufacture and sell its COVID-19 prevention and treatment drug in Japan.
AstraZeneca K.K., the Osaka-based unit, is seeking fast-track approval for the AZD7442 drug, known abroad as Evusheld.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see this support page.
We humbly apologize for the inconvenience.
In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.
SUBSCRIBE NOW
PHOTO GALLERY (CLICK TO ENLARGE)
With your current subscription plan you can comment on stories. However, before writing your first comment, please create a display name in the Profile section of your subscriber account page.